155 related articles for article (PubMed ID: 27879369)
1. Response Assessment Criteria and Their Applications in Lymphoma: Part 2.
Moghbel MC; Mittra E; Gallamini A; Niederkohr R; Chen DL; Zukotynski K; Nadel H; Kostakoglu L
J Nucl Med; 2017 Jan; 58(1):13-22. PubMed ID: 27879369
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic accuracy of FDG PET/CT for clinical evaluation at the end of treatment of HL and NHL: a comparison of the Deauville Criteria (DC) and the International Harmonization Project Criteria (IHPC).
Fallanca F; Alongi P; Incerti E; Gianolli L; Picchio M; Kayani I; Bomanji J
Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1837-48. PubMed ID: 27154522
[TBL] [Abstract][Full Text] [Related]
3. PET/CT for Lymphoma Post-therapy Response Assessment in Other Lymphomas, Response Assessment for Autologous Stem Cell Transplant, and Lymphoma Follow-up.
Karls S; Shah H; Jacene H
Semin Nucl Med; 2018 Jan; 48(1):37-49. PubMed ID: 29195616
[TBL] [Abstract][Full Text] [Related]
4. PET/CT: appropriate application in lymphoma.
Wang X
Chin Clin Oncol; 2015 Mar; 4(1):4. PubMed ID: 25841711
[TBL] [Abstract][Full Text] [Related]
5. PET/CT for Lymphoma Post-therapy Response Assessment in Hodgkin Lymphoma and Diffuse Large B-cell Lymphoma.
Kobe C; Dietlein M; Hellwig D
Semin Nucl Med; 2018 Jan; 48(1):28-36. PubMed ID: 29195615
[TBL] [Abstract][Full Text] [Related]
6. Usual and unusual pitfalls of 18F-FDG-PET/CT in lymphoma after treatment: a pictorial review.
Dubreuil J; Salles G; Bozzetto J; Tordo J; Djaïleb L; Berriolo-Riedinger A; Leenhardt J; Giammarile F; Meignan M; Skanjeti A
Nucl Med Commun; 2017 Jul; 38(7):563-576. PubMed ID: 28570287
[TBL] [Abstract][Full Text] [Related]
7. When should FDG-PET be used in the modern management of lymphoma?
Barrington SF; Mikhaeel NG
Br J Haematol; 2014 Feb; 164(3):315-28. PubMed ID: 24131306
[TBL] [Abstract][Full Text] [Related]
8. Overview of early response assessment in lymphoma with FDG-PET.
MacManus MP; Seymour JF; Hicks RJ
Cancer Imaging; 2007; 7(1):10-8. PubMed ID: 17766210
[TBL] [Abstract][Full Text] [Related]
9. PET/CT in Lymphoma: Current Overview and Future Directions.
Cheson BD
Semin Nucl Med; 2018 Jan; 48(1):76-81. PubMed ID: 29195620
[TBL] [Abstract][Full Text] [Related]
10. PET-CT in Staging, Response Evaluation, and Surveillance of Lymphoma.
Thanarajasingam G; Bennani-Baiti N; Thompson CA
Curr Treat Options Oncol; 2016 May; 17(5):24. PubMed ID: 27032646
[TBL] [Abstract][Full Text] [Related]
11. Renal Masses Detected on FDG PET/CT in Patients With Lymphoma: Imaging Features Differentiating Primary Renal Cell Carcinomas From Renal Lymphomatous Involvement.
Nicolau C; Sala E; Kumar A; Goldman DA; Schoder H; Hricak H; Vargas HA
AJR Am J Roentgenol; 2017 Apr; 208(4):849-853. PubMed ID: 28095016
[TBL] [Abstract][Full Text] [Related]
12. Prediction of outcome in pediatric Hodgkin lymphoma based on interpretation of
Isik EG; Kuyumcu S; Kebudi R; Sanli Y; Karakas Z; Cakir FB; Unal SN
Ann Nucl Med; 2017 Nov; 31(9):660-668. PubMed ID: 28741053
[TBL] [Abstract][Full Text] [Related]
13. Posttreatment PET/CT Rather Than Interim PET/CT Using Deauville Criteria Predicts Outcome in Pediatric Hodgkin Lymphoma: A Prospective Study Comparing PET/CT with Conventional Imaging.
Bakhshi S; Bhethanabhotla S; Kumar R; Agarwal K; Sharma P; Thulkar S; Malhotra A; Dhawan D; Vishnubhatla S
J Nucl Med; 2017 Apr; 58(4):577-583. PubMed ID: 27754902
[TBL] [Abstract][Full Text] [Related]
14. PET/CT for Staging; Past, Present, and Future.
El-Galaly TC; Gormsen LC; Hutchings M
Semin Nucl Med; 2018 Jan; 48(1):4-16. PubMed ID: 29195617
[TBL] [Abstract][Full Text] [Related]
15. Predicting Pathologic Response of Esophageal Cancer to Neoadjuvant Chemotherapy: The Implications of Metabolic Nodal Response for Personalized Therapy.
Findlay JM; Bradley KM; Wang LM; Franklin JM; Teoh EJ; Gleeson FV; Maynard ND; Gillies RS; Middleton MR
J Nucl Med; 2017 Feb; 58(2):266-275. PubMed ID: 27635027
[TBL] [Abstract][Full Text] [Related]
16. Whole-body MRI, FDG-PET/CT, and bone marrow biopsy, for the assessment of bone marrow involvement in patients with newly diagnosed lymphoma.
Albano D; Patti C; Lagalla R; Midiri M; Galia M
J Magn Reson Imaging; 2017 Apr; 45(4):1082-1089. PubMed ID: 27603267
[TBL] [Abstract][Full Text] [Related]
17. Intra- and inter-observer agreement in the visual interpretation of interim 18F-FDG PET/CT in malignant lymphoma: influence of clinical information.
Arimoto MK; Nakamoto Y; Higashi T; Ishimori T; Ishibashi M; Togashi K
Acta Radiol; 2018 Oct; 59(10):1218-1224. PubMed ID: 29333861
[TBL] [Abstract][Full Text] [Related]
18. PET imaging for response assessment in lymphoma: potential and limitations.
Schöder H; Moskowitz C
Radiol Clin North Am; 2008 Mar; 46(2):225-41, viii. PubMed ID: 18619378
[TBL] [Abstract][Full Text] [Related]
19. Beyond the lymph nodes: FDG-PET/CT in primary extranodal lymphoma.
Sin KM; Ho SK; Wong BY; Gill H; Khong PL; Lee EY
Clin Imaging; 2017; 42():25-33. PubMed ID: 27875758
[TBL] [Abstract][Full Text] [Related]
20. Integrating PET and PET/CT into the risk-adapted therapy of lymphoma.
Kasamon YL; Jones RJ; Wahl RL
J Nucl Med; 2007 Jan; 48 Suppl 1():19S-27S. PubMed ID: 17204717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
